DeCure for Attention deficit hyperactivity disorder
DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for attention deficit hyperactivity disorder — screening already-approved drugs against its 38-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAttention deficit hyperactivity disorder maps to a 38-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for attention deficit hyperactivity disorder is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
FES proto-oncogene, tyrosine kinase (FES) — FES is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet studrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3CBL · 1.75 Å · ligand STAUROSPORINE (STU). Experimental structure, not a prediction.
What the evidence adds up to
The three abstracts provided are review articles, not primary clinical trials, so no concrete numbers for survival, response rates, or sample sizes are reported. The 2013 review discusses indications, efficacy, adverse effects, and dosing regimens for pharmacological treatments of ADHD but gives no specific data. The 2000 consensus statement notes that careful medication management can result in noticeable improvement in several measures with little risk of adverse events, but it also states that treatment of ADHD remains controversial and that more research is needed. The 2020 review states that major pharmacological treatments include stimulants (amphetamines and methylphenidate) and non-stimulants (atomoxetine and others), and that studies have demonstrated the most improvement in functioning and reduction of symptoms from a combination of pharmacological and behavioural treatment, though medication management alone is significantly more effective than behavioural therapy strategies.
No single drug is being repurposed in these abstracts; they are general overviews of established ADHD pharmacotherapy. No efficacy claims beyond the general statements above can be extracted, and no contradictory or disappointing results are reported because the abstracts do not present any trial outcomes. The reviews do not address long-term outcomes, comparative effectiveness between drug classes, or the management of non-response.
What is still missing from this evidence base, as reflected in these reviews, is any data from head-to-head trials of repurposed agents, any stratification of patients by age, comorbidity, or genetic subtype, and any funding for trials that move beyond established stimulant and non-stimulant categories. The abstracts themselves call for more research but do not specify what that research should cost or how it should be designed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Progress in Neurology and Psychiatry · 2013 · 8 citations · open access
Pharmacological treatments for ADHD
AbstractAbstract In the second of this series of updated reviews on the major psychiatric drug groups, in association with the College of Mental Health Pharmacy (CMHP; www.cmhp.org.uk ), Caroline Parker discusses the use of drug treatments in the management of attention deficit hyperactivity disorder (ADHD), including their indications, efficacy, adverse effects and recommended dosing regimens.
The National Institutes of Health Attention-Deficit/Hyperactivity Disorder Consensus Statement: Implications for Practitioners and Scientists
AbstractAlthough the concept of pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) was first introduced more than 60 years ago, treatment of this disorder remains more controversial than ever. It is hoped, however, that the recent Consensus Development Conference (CDC) Statement on the diagnosis and treatment of ADHD will not only help answer some of the questions surrounding management of this disorder, but also lend needed scientific weight to debate in this area. While more research in ADHD is needed, the CDC participants pointed to a solid body of evidence showing that careful medication management can result in noticeable improvement in several measures, with little risk of adverse events.
Novel Research in Sciences · 2020 · 0 citations · open access
Pharmacology of Attention-Deficit/ Hyperactivity Disorder Treatments
AbstractThere is a significant body of research on the topic of treatments for attention-deficit/hyperactivity disorder in children, adolescents, and adults. Major pharmacological treatments include stimulants (amphetamines and methylphenidate) and non-stimulants (atomoxetine and others). There are also forms of non-pharmacological treatment, including behavioral and psychosocial therapies. Studies have demonstrated the most improvement in functioning and reduction of symptoms because of a combination of pharmacological and behavioral treatment, however on its own, medication management has proven to be significantly more effective than behavioral therapy strategies. This review covers recent trends in Treatments and Pharmacology of Attention-Deficit/Hyperactivity Disorder.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
